Roxindole, a potential antidepressant. I. Effect on the dopamine system

Journal of Neural Transmission

Volumn 103, Issue 5, 1996, Pages 627-641

  Maj, J ^a   Kolodziejczyk K ^a   Rogoz Z ^a   Skuza, G ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressant activity; Dopamine system; Mice; Rats; Roxindole

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; APOMORPHINE; DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; ROXINDOLE; SPIPERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; FORCED SWIMMING TEST; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; APOMORPHINE; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; INDOLES; MALE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; PYRIDINES; RATS; RATS, WISTAR; STEREOTYPED BEHAVIOR;

EID: 0029801333     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01273159     Document Type: Article

References (29)

1. Andén N-E, Golembiowska-Nikitin K, Thornström U (1982) Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively. Naunyn Schmiedebergs Arch Pharmacol 321: 100-104
2. Bartoszyk GD, Harting J, Minck KO (1996) Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist. J Pharmacol Exp Ther 276: 41-48
3. Benkert O, Gründer G, Wetzel H (1992) Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 25: 254-260
4. Bravi D, Davis TL, Mouradian MM, Chase TN (1993) Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980. Mov Disord 8: 195-197
5. Broekkamp CLE, Oosterloo SK, Berendsen HHG, van Delft AML (1988) Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch Pharmacol 338: 191-195
6. Costall B, Naylor RJ (1972) Possible involvement of noradrenergic area of the amygdala with stereotyped behaviour. Life Sci 11 Part I: 1135-1146
7. Delini-Stula A, Morpurgo C (1968) Influence of amphetamine and scopolamine on the catalepsy induced by diencephalic lesions in rats. Int J Neuropharmacol 7: 391-397
8. Gerlach J (1991) New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 17: 289-309
9. Gründer G, Wetzel H, Hammes E, Benkert O (1993) Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology 111: 123-126
10. Harting J, Minck KO (1989) Pharmacological characterization of the dopamine autoreceptor agonist roxindole. Naunyn Schmiedebergs Arch Pharmacol 339: R 104
11. Jaspers Ch, Benker G, Reinhardt W, Cissewski K, Lederbogen S, Schröder HG, Reinwein D (1992) A new non-ergot dopamine agonist (roxindol) for treatment of prolactinoma: first results. Acta Endocrinol 126 [Suppl 4]: 131
12. Kasper S, Fuger J, Zinner HJ, Bäuml J, Möller HJ (1992) Early clinical results with the neuroleptic roxindole (EMD 49 980) in the treatment of schizophrenia - an open study. Eur Neuropsychopharmacol 2: 91-95
13. Klimek V, Maj J (1989) Repeated administration of antidepressants enhances agonist affinity for mesolimbic D2 receptors. J Pharm Pharmacol 41: 555-558
14. Klimke A, Klieser E (1991) Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (roxindol). Pharmacopsychiatry 24: 107-112
15. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99-113
16. Maj J (1984) Central effects following repeated treatment with antidepressant drugs. Pol J Pharmacol Pharm 36: 87-89
17. Maj J, Rogóż Z, Skuza G, Sowińska H (1984) Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine. J Pharm Pharmacol 36: 127-130
18. Maj J, Rogóż Z, Skuza G, Sowińska H (1985) The effects of repeated treatment with antidepressant drugs on the action of D-amphetamine and apomorphine in rats. In: Kelemen K, Magyar K, Vizi ES (eds) Neuropharmacology 1985. Akadémiai Kiadó, Budapest, pp 133-139
19. Maj J, Rogóż Z, Skuza G, Sowińska H (1989) Antidepressants given repeatedly increase the behavioral effect of dopamine D-2 agonist. J Neural Transm [Gen Sect] 78: 1-8
20. Maj J, Sarnek J, Klimek V, Rawlłów A (1976) On the anticataleptic action of cyproheptadine. Pharmacol Biochem Behav 5: 201-205
21. Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379-391
22. Protais P, Costentin J, Schwartz JC (1976) Climbing behaviour induced by apomorphine in mice: a simple test for the study dopamine receptors in striatum. Psychopharmacology 50: 1-6
23. Pugsley TA, Christofferson CL, Corbin A, DeWald HA, Demattos S, Meltzer LT, Myers SL, Shih Y-H, Whetzel SZ, Wiley JN, Wise LD, Heffner TG (1992) Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist. J Pharmacol Exp Ther 263: 1147-1158
24. Serra G, Argiolas A, Klimek V, Fadda F, Cessa GL (1979) Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity. Life Sci 25: 415-424
25. 2 receptors following long-term treatment with roxindole. Eur J Pharmacol 257: 67-72
26. Seyfried ChA, Greiner HE, Haase AF (1989) Biochemical and functional studies on EMD 49 980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems. Eur J Pharmacol 160: 31-41
27. Spyraki Ch, Fibiger HC (1981) Behavioural evidence for supersensivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 74: 195-206
28. Wiedemann K, Kellner M, Krieg J-C, Holsboer F (1992) Effects of the dopamine autoreceptor agonist roxindole in patients with depression. Clin Neuropharmacol 15 [Suppl 1B]: 175B
29. Willner P (1983) Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Res Rev 6: 237-246